The Indian pharma industry is now placing a major bet on biosimilars, which is hotting up after generics. With the expiration ...

Add Yahoo as a preferred source to see more of our stories on Google. Draft guidance from the FDA would allow companies to scale back on the studies and trials needed to prove that a biosimilar ...

Nine out of 10 prescriptions are filled by generic drugs — FDA-approved carbon copies of brand-name drugs with expired patents. Over the last 30 years, generic drugs have saved trillions of dollars ...

A new NITI Aayog report proposes "BioPharmaNext" and a ₹50,000-crore growth fund to transition India's pharmaceutical sector ...

Picture this: A cancer patient in a district hospital, once sent abroad for care, now begins treatment with cell therapy—developed and produced just a few hours away, in a domestic biomanufacturing ...

Indian pharma is entering its next growth phase as a new segment gains traction. We analyse four companies building this ...

Generic drug suppliers weigh predictable and unpredictable factors that could impact the category in 2025. “This is the latest example of our actions to expand our portfolio in growing therapeutic ...

WASHINGTON (Reuters) - Cheaper, generic versions of more complex protein-based drugs will need more data than simpler compounds to prove their safety and effectiveness, a U.S. Food and Drug ...

The Food and Drug Administration said it will be taking steps to speed up the approval process for developing generic biological drugs, an effort aimed at increasing cheaper competition among ...

Generic Drugmakers Oppose 10 Years Exclusivity for Biologics in US-Mexico Deal As part of a preliminary trade deal between the US and Mexico, to update the 24-year-old North American Free Trade ...